Email: cspc@cspc.cn
News
News Center
Jul. 27
2026
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) ACCEPTED BY THE NMPA
Jul. 24
VOLUNTARY ANNOUNCEMENT - PALIPERIDONE PALMITATE INJECTION RECEIVES MARKETING APPROVAL
Jul. 22
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6026 INJECTION FOR THE TREATMENT OF HPV TYPE 16- OR 18-RELATED CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELI
Jul. 17
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR TRASTUZUMAB ENVEDOTIN INJECTION ACCEPTED BY THE NMPA
Jul. 16
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF PLATINUM-RESISTANT ADVANCED OVARIAN CANCER, PRIMARY PERITONEAL CANCER, AND FAL
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) FOR THE TREATMENT OF EPITHELIOID HAEMANGIOENDOTHELIOMA OFFICIALLY IN
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
